935841-80-8 Usage
Uses
Used in Pharmaceutical Industry:
N-[(1R,2R)-2-Hydroxy-3-[(2-Methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]carbamic Acid 1,1-Dimethylethyl Ester is used as a key intermediate in the synthesis of 1-epi-Darunavir (D193505), a second-generation HIV-1 protease inhibitor. N-[(1R,2R)-2-Hydroxy-3-[(2-Methylpropyl)[(4-nitrophenyl)sulfonyl]aMino]-1-(phenylMethyl)propyl]carbaMic Acid 1,1-DiMethylethyl Ester contributes to the development of potent antiretroviral medications, which are essential in the ongoing battle against HIV/AIDS. Its role in the synthesis process is vital for creating effective treatments that can combat drug resistance and improve the quality of life for those affected by the disease.
Check Digit Verification of cas no
The CAS Registry Mumber 935841-80-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,5,8,4 and 1 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 935841-80:
(8*9)+(7*3)+(6*5)+(5*8)+(4*4)+(3*1)+(2*8)+(1*0)=198
198 % 10 = 8
So 935841-80-8 is a valid CAS Registry Number.
935841-80-8Relevant academic research and scientific papers
Pharmacokinetics of protease inhibitors and other drugs
-
Page/Page column 6; sheet 9, (2009/01/20)
A method for modulating at least one pharmacokinetic property of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons comprising the prot
IMPROVING THE PHARMACOKINETICS OF PROTEASE INHIBITORS AND OTHER DRUGS
-
Page/Page column 15-16, (2008/06/13)
A method for modulating at least one pharmacokinetic property of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the protease inhibitor.
